Searching the Resource Information Network

Our searching services are busy right now. Please try again later

  • Register
X
Forgot Password

If you have forgotten your password you can enter your email here and get a temporary password sent to your email.

X

Leaving Community

Are you sure you want to leave this community? Leaving the community will revoke any permissions you have been granted in this community.

No
Yes

 PMID:29679653  

Effects of selective serotonin-reuptake inhibitors (SSRIs) on human villous trophoblasts syncytialization.

Hélène Clabault | Denis Flipo | Jean Guibourdenche | Thierry Fournier | J Thomas Sanderson | Cathy Vaillancourt
Toxicology and applied pharmacology | 2018

Selective serotonin-reuptake inhibitors (SSRIs) are the most commonly prescribed antidepressants during pregnancy. The human placenta is a highly specialized organ supporting normal growth and development of the fetus. Therefore, this study aims to analyze the effects of SSRIs on villous cytotrophoblasts cells, using BeWo cells and human placental trophoblast cells in primary culture. The SSRIs fluoxetine and its metabolite norfluoxetine, sertraline and venlafaxine did not affect BeWo cell proliferation and viability, nor the percentage of M30-positive (apoptotic) primary trophoblast cells. None of the SSRIs affected basal or forskolin-stimulated BeWo cell fusion, whereas sertraline and venlafaxine increased the fusion of primary villous trophoblasts. Sertraline and venlafaxine also modified human chorionic gonadotropin beta (β-hCG) secretion by BeWo cells, whereas none of the SSRIs affected β-hCG secretion in primary trophoblasts. Norfluoxetine increased CGB (chorionic gonadotropin beta) and GJA1 (gap junction protein alpha 1) levels of gene expression (biomarkers of syncytialization) in BeWo cells, whereas in primary trophoblasts none of the SSRIs tested affected the expression of these genes. This study shows that SSRIs affect villous trophoblast syncytialization in a structure- and concentration-dependent manner and suggests that certain SSRIs may compromise placental health. In addition, it highlights the importance of using primary trophoblast cells instead of "trophoblast -like" cell lines to assess the effects of medications on human villous trophoblast function.

Pubmed ID: 29679653

Research resources used in this publication

None found

Additional research tools detected in this publication

Antibodies used in this publication

None found

Associated grants

None

Publication data is provided by the National Library of Medicine ® and PubMed ®. Data is retrieved from PubMed ® on a weekly schedule. For terms and conditions see the National Library of Medicine Terms and Conditions.

This is a list of tools and resources that we have found mentioned in this publication.


geNORM (tool)

RRID:SCR_006763

Software to determine most stable reference (housekeeping) genes from set of tested candidate reference genes in given sample panel. From this, gene expression normalization factor can be calculated for each sample based geometric mean of user-defined number of reference genes.

View all literature mentions

Biogazelle (tool)

RRID:SCR_012617

At Biogazelle, we are dedicated to accelerate the understanding of the transcriptome through excellence in science and technology. We are convinced that unravelling the coding and non-coding regions of the genome will help researchers, clinicians, plant breeders, and other actors of the scientific community to get better answers to their questions. It is our mission to develop data-analysis software tools, and to carefully select the best analytical platforms to offer customized RNA gene expression services. Our service lab activities support the life science market at every level of the entire process: from discovery to validation of biomarkers, from optimal experiment design to extensive analysis and interpretation of results, from PCR assay design to research-use-only kits. We are a young and dynamic company, eager to learn and to teach. Our continuous research, solid track record, and worldwide network keep Biogazelle at the forefront of new developments, making new instruments and cutting edge technologies accessible to all our customers. Each project is handled by experts and is fully customized to suit the objectives of the project and to accommodate specific requirements. The service portfolio ranges from sample preparation to data analysis using rigorous MIQE compliant procedures, high-throughput and validated laboratory methods, qbase+ data analysis software, and state-of-the-art analytical tools.

View all literature mentions